welcome, Thank you, Roger, everyone. and
our our quarter company EBITDA revenue EBITDA I business second positive ADHD we gained into posted recent growth. prescription the the for quarter, weekly trajectory all adjusted at the like for the and I'd Rx has consecutive numbers this momentum and quarter very And come. am specifics. extremely another I'm to of report with February. change years we Achieving franchise More Aytu enthusiastic trends off, is share positively March get key particularly as in the Aytu in that to positive consecutive strong here adjusted pleased continued milestone First how in of about into to helps the wide as current momentum time second on
today's the by quarter the which quarterly revenue to increased outlined $XX $XX.X year-ago due experienced continuing along access our net in growth execution segments. by segment to to RxConnect, in strong the patient and million, our compared million, we XX%, leverage release, our press proprietary novel driven market XX% generating As The to of Rx revenue with Rx capitalizing force through program, sales are on. shortages, the ADHD and stimulant associated with some we're tailwinds Aytu performance
improvement $X.X of had quarter period Rx $X.X million the segment net Further portfolio sequential for to and growing our was quarter adjusted segment, increased X.X% Rx million scripts in adjusted sequentially, ADHD the fiscal XX% EBITDA increase and EBITDA positive rose of a our Within pediatric for products. while of first the negative revenue demand reported from the highlighting compared the XXXX. a year-ago also
the which quarter, positive segment the a prescription EBITDA. that This is explain on had in in I'll now bit. third consecutive adjusted more has business
negative contribution XX% the improvement objective resulting our profitability on the on adjusted segment continues with On the Health channels, improve efficient, more a significant a to side, EBITDA. in Consumer to segment higher focus online execute in margin segment's sales
expand our profitable the thereafter our segment to segment near-term their to forward we impacted and this adjusted Consumer flow. to and direct we the from this believe are likely revenue prepare e-commerce gains last sales OTC in out positive Further, Health to we on well will as more we well. the moment mail propel focus I'll quarter, initiative branding channel. and upon medicines bit As build as a discussed as later channel generating be launch positioned phase Health a on recent C'rcle we more free EBITDA year, cash and this
quarter a All which XXXX, of to quarter, EBITDA million told, million compares last than like forward. negative a more now would note adjusted for the $X.X second This million in the million. the second positive with the EBITDA during when highlights a forma year's positive has was development of to also I associated an company that $X.X company improvement $X the of programs. operating EBITDA that expenditures generated Aytu adjusted pro $X clinical exclude adjusted residual going the you strength suspended
expected enzastaurin Ehlers-Danlos the is to million business the syndrome. adjusted allowing On October projected save clinical us Vascular accelerating company's ARXXX XX an achieving strategy continue programs, for commercial growth development last trajectory positive We of year, of the aimed our the future our including profitability. $XX or we over the and of upward important at of EBITDA. of shift study announced suspension company to costs, our The in treatment suspended
will maximizing which has of to our synergies EBITDA down to driving adjusted revenue, in path now With growing second on that expenses, efforts hand, markedly clear. our path refocused and have serve our profitability. quarter become accelerate We all
beginning Let's segment. the our business dive commercial into a with bit more, Rx
within we reminder, operate primarily in a pediatrics. and Rx two areas, ADHD the segment, As therapeutic
orally first extended-release only and treatment the with amphetamine This Cotempla tablets, start Adzenys portfolio methylphenidate for XR-ODT the FDA Let's ADHD. includes disintegrating and respectively ADHD. and of XR-ODT, approved
our formulated are utilize technology stimulant that oral release modified delivery extended in tablets medications micro particle proprietary drug patient-friendly platform. disintegrating These release
revenue prescriber scripts million X% period We patient as the from believe revenue the ago an to up largely net issues compared characterization during contributed however, and is and year $XX.X sequentially. a to a the During holidays. of impact actually throughout due the sustained of our increase number, the the number ADHD There's year a of shipping quarter the revenue, weather bit better is script were little down quarter, X% the in of demand and end in inclement sequentially. products X% resulting over noise
logistics the impacted storm significant that US that at calendar of winter end in Remember there the a XXXX. was
of that So some shipments. delayed our
up timing quarter. the current catch the see continue issue to to to this for the in tailwinds market itself expect provide The surrounding ADHD dynamics company. of We
an in ADHD as market increase growth continue see we the we to diagnosis. see First, in overall
to company, data prescriptions seen rise Health, Trilliant year X.X% adults XXXX, during According the the double Adderall XX.X% health before. for rose the
the Additionally, I delays and the supply manufacturer various quarter XR Adderall about impact remain. disruptions generic last talked from still
Just discussing of last week, a Bloomberg article once the impact ongoing reported again shortages. these
market uninterrupted. quarters and our Fortunately, of and mind few robust evidence has in and to supply the share fact, share remained past we're supply disruptions enabled competitive the believe over We gain data. have Adzenys seeing in that the
capture to bioequivalent amphetamine our of so is share Adzenys as Adderall brand continue XR, the remnants extended-release additional remain. as reminder, to to a approved shortage the As well is positioned
how week and the To further registered ongoing we're the February note highlight This I'll week. XX% for total the the registered is the is Adderall weekly continuing X,XXX over up highest XR TRx prescriptions. execution, Adzenys and is from XXth, brand. by that ending far This an for previous to high shortage leverage ever all-time our level
also & shortages now of Cotempla with the over is and TRxs week. highest of among hearing previous methylphenidate week. generic. numbers This Johnson same know X,XXX the Johnson's Concerta-authorized that discontinuation We're of up its weekly registered XX% over
time. providing tailwinds for So, ADHD of some market that we significant our both may believe have now factors brands persist
the again, over on are XXth, we're our level. have year. the year-to-date ending at very And the all-time across Rx the side with over To four up XX% entire high scripts tremendous combined weeks weeks our an preceding XX% say least, ADHD brands. For momentum portfolio, February and we last up our four prescription
and and sales delivering refreshed job to creating tailwinds, our drive has done team macro on building I believe headlined tremendous tools a the growth. Beyond highly and by motivated RxConnect a the team
the I'll began remind revamping the nearly of you of salesforce. the we that acquisition Neos two ago, following years process
stronger for mindset now turned sales over sales transition change outsized performance preference and large representatives time, took This the for it and With a of begun we highly dividends compensation team. the sales but pay still and team. of former a the paying across newer-to-industry portion has motivated new Neos model,
commercial X,XXX the across RxConnect. drive RxConnect, lies prescriptions our on all platform. key the key RxConnect part with pharmacies have stakeholders, team, in markets seek through success with that our value a platform. for real we to conjunction roughly country network so of Aytu creates With we our In
the margin The in the in improvement a does value truly XX% refills filled Xx health platform Aytu's nearly and for Aytu, drive in the been increase patient providers by inception co-payments, course, reduction to of per the platform, purpose results patients. Rx, has program. care patients, net prescription and outside which, Aytu XX% RxConnect Compared since a in out-of-pocket prescriptions than more of
predictable. attributed With platform hassles are remain this consistent the payers Aytu can the with that with to growth RxConnect, dealing removed. co-pays and largely prescriber of many Further, patients' associated be fact
away. goes experience the patients writing often clinicians In branded largely when filling friction, and scripts and
into Going evaluating leverage bring and forward, we new products RxConnect will continue current the portfolio. products our to are the to
we're with these such but position. script Again, a creating has we're we where great going us in I'm with into work team putting where and grateful I'm lot this recent strong trends. for gone of pleased excited A entire the momentum for are, most about
profitability. a note to on improve the Before I is we transition quick Adzenys transfer at both expected Pediatric which our the that and to Portfolio, further underway, just have manufacturing Cotempla
we other back conduct prospective the the the required with the bioequivalent reported manufacturer, well studies work. underway As contract September, and in including is of process
profit This in our producing More of a the of margin front. is XX% follow in will with to as meaningful XXXX. or ADHD by the this on goal are our step but It change pleased process gross CMO progress our outsourcing to having products if achieved, finalized further this P&L. the stands everything our improve more, we ADHD brands calendar that, improve continues,
complementary now and infants which two vitamins transition fluoride includes deficiency. various product children Portfolio, combinations fluoride with our for in multivitamin to formulations Tri-Vi-Flor, lines fluoride-based of Let's and containing Poly-Vi-Flor, Pediatric prescription,
Karbinal offer suspension an treat and for conditions years released carbinoxamine markets features and competitive also clinical two both patient indicated generic These and over ER, serve numerous pediatric established older. products. distinct market patients large to extended based benefits branded and antihistamine allergic We products
from growth During in quarter. achieved year-over-year revenue that a the the from to revenue first pediatric we the pediatric achieved in with revenue $X.X products in XX% ramping growth prescription million. addition was to line quarter, we XX% in This
just the continues. growth So
we to as are Since RxConnect Aytu RxConnect TVF growth. continue added Similar the platform the growth drivers execution well to sales platform, trajectory. and our product the PVF the to key These significant grown here as we ADHD prescription demonstrate and for prescription force improved are providing tailwinds leverage. portfolio, remarkable have improvements
access from, basis CDC fluoride percentage that only and has US water continue even recent supplementation. the of states some most fluoride both existing that like continually We're their expansion the multivitamin data XX% of in Poly-Vi-Flor, or as Jersey is which in need The that sales. will the mid-teens to population will geographic opportunities to fluoride less. believe New the areas in evaluating shows to in we new We Tri-Vi-Flor additional grow across line serve for geographies we look growth as and
context our same period XXth, up year, recent they're on week Again, at up growth of over prescription note Poly-Vi-Flor over additional over ending Tri-Vi-Flor I'll while look we tremendous provide scripts are the brands, Karbinal pediatric the using growth scripts To are growth year-to-date February also and the the the experiencing. last Combined XXX% when XX%.
achieving the our Overall, we're I'm traction with segment. pleased RX across
RX experienced EBITDA continued we and $X.X with place, EBITDA. improvement consecutive the positive XX% With margin gross quarter we expect positive positive and reductions in forward. cost mentioned, growth, in continue adjusted generated segment EBITDA, revenue going in our million As second the third quarters to measures a growth quarter adjusted
transition Let's our Consumer now. Health to segment
As a management large national competing hair reminder, categories with our products Health, large such brands. branded digestive product in value-based allergy, loss, competing focus as diabetes on and core all health, is Consumer within
the platforms, on We and sell including directly branded through e-commerce to Amazon consumers websites platform.
primarily consumer the products sells proprietary which and sales mail. through platform, our on focuses direct Additionally, segment marketing
profitability touched has on higher our sales been focus margin contribution segment improve online last to we Consumer channels. on more quarter, efficient, As a Health objective with
EBITDA to may e-commerce As impact in Health near-term, just direct negatively improved but we the a focus medicines our channel. the drive the and higher channel through result, in will revenues phasing segment. on OTC within mail are out Consumer This specifically order profitability
year-over-year by OTC Focusing to in $X.X a ago experiencing nearly e-commerce efforts XX% despite was portfolio, I'll which segment X% or resulted the quarter, more improvement were our adjusted profitable over achieved a improving revenues the EBITDA This million. in out XX% segment total segment $XXX,XXX. for on year decrease point this
to to growth are efforts profitable sustainable in this segment off. drive beginning Our pay
of Health in seeking to brand big officially plan, establishing we will of alluded As addressing part C'rcle we counter Health value called a family medicines initiative based have represent C'rcle expected yielding our and brand to brand range creating through sales, later value a driving growth annuity a This products repeat a common are more the brands launch higher brand and we Health, families overall year. create past brand recognized one-stop value. OTC expect addressing single equity. of build family Consumer this will the which to a a conditions. over ultimately collective conditions everyday customer shop value medicine more Showcasing is for common, thus margins
formation add integrate existing to approach all products, as of the we More products brand family. expect rebrand of part follow As the and C'rcle the those Launch. we new into C'rcle to the C'rcle brand,
to adjusted consecutive revenue turn second with let build organization. just entire continues opportunity strong truly The team execution-oriented of the quarter me led and incredibly rally say, to company-wide a I over which EBITDA. proud Mark, it positive our I the to growth Before great around has to company, how am
the to further with a for very further to cost are shareholder February to and value. stronger strong much operational trends the the in remainder again, improvements in improvements With middle And the our and of initiatives encouraging fiscal position through margin financial long-term are drive we during growth, year, further add position. prescription of place coupled reductions
overview Oki the With to to me now Mark? over complete, some color Mark let additional CFO, turn it that our numbers. for
